Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for PHMMF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 193.08M
March 31, 2026 193.40M
December 31, 2025 196.40M
September 30, 2025 172.33M
June 30, 2025 150.35M
March 31, 2025 152.14M
December 31, 2024 160.01M
September 30, 2024 161.15M
June 30, 2024 144.84M
March 31, 2024 172.50M
December 31, 2023 179.57M
September 30, 2023 184.60M
June 30, 2023 201.72M
March 31, 2023 198.96M
December 31, 2022 194.69M
September 30, 2022
June 30, 2022 205.64M
March 31, 2022 246.55M
December 31, 2021 229.58M
September 30, 2021 256.26M
June 30, 2021 257.02M
March 31, 2021 246.88M
December 31, 2020 239.22M
September 30, 2020 231.30M
June 30, 2020 256.20M
Date Value
March 31, 2020 190.49M
December 31, 2019 23.45M
September 30, 2019 25.52M
June 30, 2019 44.79M
March 31, 2019 15.47M
December 31, 2018 30.72M
September 30, 2018 30.39M
June 30, 2018 17.14M
March 31, 2018 19.54M
December 31, 2017 38.14M
September 30, 2017 16.16M
June 30, 2017 22.39M
March 31, 2017 12.76M
December 31, 2016 15.07M
September 30, 2016 11.91M
June 30, 2016 9.591M
March 31, 2016 7.464M
December 31, 2015 8.287M
September 30, 2015 44.13M
June 30, 2015 25.56M
March 31, 2015 33.00M
December 31, 2014 42.95M
September 30, 2014 46.00M
June 30, 2014 48.51M
March 31, 2014 45.86M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Oryzon Genomics SA 16.79M
Grifols SA 586.51M
ACADIA Pharmaceuticals, Inc. 956.47M
Alkermes Plc 656.58M
Alnylam Pharmaceuticals, Inc. 3.308B